GSK (LON:GSK) Insider Julie Brown Acquires 8 Shares

GSK plc (LON:GSK) insider Julie Brown bought 8 shares of the business’s stock in a transaction that occurred on Tuesday, September 9th. The stock was purchased at an average cost of GBX 1,486 per share, for a total transaction of £118.88.

Julie Brown also recently made the following trade(s):

• On Monday, August 11th, Julie Brown purchased 9 shares of GSK stock. The shares were purchased at an average cost of GBX 1,408 per share, with a total value of £126.72.

GSK Stock Down 0.3%

GSK stock opened at GBX 1,485.98 on Thursday. The business’s 50-day simple moving average is GBX 1,424.58 and its two-hundred day simple moving average is GBX 1,432.24. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The company has a market cap of £59.85 billion, a PE ratio of 1,796.83, a PEG ratio of 1.24 and a beta of 0.31. GSK plc has a fifty-two week low of GBX 1,242.50 and a fifty-two week high of GBX 1,675.

GSK (LON:GSK) last released its earnings results on Wednesday, July 30th. The company reported GBX 75.30 EPS for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Equities analysts anticipate that GSK plc will post 175.980975 EPS for the current year.

Analysts Set New Price Targets

Several analysts have commented on GSK shares. JPMorgan Chase & Co. decreased their price objective on shares of GSK from GBX 1,460 to GBX 1,400 and set an “underweight” rating for the company in a research note on Monday, August 4th. Shore Capital reissued a “buy” rating and set a GBX 2,100 target price on shares of GSK in a report on Wednesday, August 27th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a GBX 1,450 price target on shares of GSK in a report on Thursday, July 31st. Finally, Berenberg Bank reaffirmed a “hold” rating and set a GBX 1,600 price target on shares of GSK in a research report on Friday, July 18th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of GBX 1,637.50.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.